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Cellular/Molecular
Targeting NMNAT1 to Axons and Synapses Transforms Its
Neuroprotective Potency In Vivo
Elisabetta Babetto,1 Bogdan Beirowski,1 Lucie Janeckova,1 Rosalind Brown,2 Jonathan Gilley,1Derek Thomson,2
Richard R. Ribchester,2 andMichael P. Coleman1
1The Babraham Institute, Laboratory of Molecular Signalling, Cambridge CB22 3AT, United Kingdom, and 2Euan MacDonald Centre for MND Research,
Edinburgh EH8 9JZ, United Kingdom
Axon and synapse degeneration are common components ofmany neurodegenerative diseases, and their rescue is essential for effective
neuroprotection. The chimeric Wallerian degeneration slow protein (WldS) protects axons dose dependently, but its mechanism is still
elusive. We recently showed that WldS acts at a non-nuclear location and is present in axons. This and other recent reports support a
model in which WldS protects by extranuclear redistribution of its nuclear NMNAT1 portion. However, it remains unclear whether
cytoplasmic NMNAT1 acts locally in axons and synapses or at a non-nuclear site within cell bodies. The potency of axon protection by
non-nuclear NMNAT1 relative to WldS also needs to be established in vivo. Because the N-terminal portion of WldS (N70) localized to
axons, we hypothesized that it mediates the trafficking of the NMNAT1 portion. To test this, we substituted N70 with an axonal targeting
peptide derived from amyloid precursor protein, and fused this to NMNAT1 with disrupted nuclear targeting. In transgenic mice, this
transformed NMNAT1 from a molecule unable to inhibit Wallerian degeneration, even at high expression levels, into a protein more
potent thanWldS, able topreserve injuredaxons for severalweeks atundetectable expression levels. PreventingNMNAT1axonal delivery
abolished its protective effect. Axonally targetedNMNAT1 localized to vesicular structures, colocalizingwith extranuclearWldS, andwas
cotransported at least partially withmitochondria.We conclude that axonal targeting ofNMNATactivity is both necessary and sufficient
to delay Wallerian degeneration, and that promoting axonal and synaptic delivery greatly enhances the effectiveness.
Introduction
Axonal degeneration is a primary or contributory component
of many neurodegenerative diseases and a promising thera-
peutic target (Raff et al., 2002; Saxena and Caroni, 2007).
Studies of the mutant mouse WldS (Wallerian degeneration
slow) (Lunn et al., 1989) established axonal degeneration as a
tightly regulated process. In this strain, the chimeric WldS
protein delays the progressive degradation of experimentally
transected nerves (Wallerian degeneration) (Waller, 1850),
preserving axons and synapses in a nonlinear, dose-dependent
fashion (Mack et al., 2001). Importantly, WldS ameliorates
axonopathy in models of various neurodegenerative condi-
tions, such as progressive motor neuronopathy, Charcot–
Marie–Tooth disease, Parkinson’s disease, and glaucoma
(Ferri et al., 2003; Samsam et al., 2003; Sajadi et al., 2004;
Howell et al., 2007; Beirowski et al., 2008), opening new ave-
nues for therapeutic approaches.
The mechanism of WldS protection remains largely elusive at
themolecular level.WldS arose from a de novo triplication, which
links the N-terminal 70 aa of the ubiquitination factor Ube4b
(N70) to the nuclear NAD-synthesizing enzyme nicotinamide
mononucleotide adenylyltransferase (NMNAT1), via a unique
18 aa sequence (Wld18) (Conforti et al., 2000). Despite its abun-
dance in the nucleus, we recently detected WldS in axons, where
it accumulates after nerve constriction (Beirowski et al., 2009).
Since axonally transported proteins typically accumulate at con-
striction sites (Cavalli et al., 2005), WldS may be transported,
either directly or by associating with vesicles or organelles. More-
over, redistribution of WldS to cytoplasm strikingly enhanced
axonal and synaptic protection (Beirowski et al., 2009), possibly
by increasing the delivery to axons and synapses whereWldSmay
function locally.
Further support for this model comes from studies of the
NMNAT1 portion of WldS. The intrinsic catalytic activity of
WldS is required for the phenotype in vitro and in vivo (Araki
et al., 2004; Jia et al., 2007; Avery et al., 2009; Conforti et al.,
2009). Nuclear NMNAT1 is not sufficient to confer axon pro-
tection in mice and has only a weak effect in Drosophila and in
primary neuronal culture relative to WldS (Conforti et al.,
2007; Avery et al., 2009; Sasaki et al., 2009b; Yahata et al.,
2009). If NMNAT1 is shifted outside the nucleus (cyt-
NMNAT1), the protection in culture is enhanced and cyt-
NMNAT1 can also protect axons in vivo when overexpressed
at least 15-fold more than WldS (Sasaki et al., 2009b). How-
ever, it remains unclear whether near-physiological levels of
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NMNAT1 are sufficient to protect injured axons in mice, and
whether the critical site is axonal or somatic.
We report here that targeting NMNAT1 to axons greatly
enhances its protective potential in vivo. We show for the first
time that even a marginal increase in NMNAT level becomes
robustly protective as long as NMNAT1 is delivered to axons,
and that preventing axonal entry abolishes this effect. Finally
we find that axonally targeted NMNAT1 colocalizes with ex-
tranuclear WldS and it is transported in coordinated move-
ment with mitochondria.
Materials andMethods
Plasmids and generation of transgenic mice. An NMNAT1 construct with
disrupted nuclear targeting, termedNLSNMNAT1,was PCRamplified
from the previously reported NLSWldS construct, carrying the R213A
and R215Amutations (Beirowski et al., 2009). The FLAG reverse primer
(BamHI site underlined, mutated stop codon in bold, FLAG tag italicized:
5-CGCGGATCCTCACTTGTCATCGTCGTCCTTGTAATCTCCCAGAG-
TGGAATGGTTGTGCTTGGC-3) (Wilbrey et al., 2008)was used together
with the following forward primers (5HindIII cloning tag underlined, start
codon in bold, axonal targeting sequence italicized).
For NLS NMNAT1-FLAG: 5-TAGATCCCAAGCTTAACTTCTC-
CCCATGGACTCAT-3 (Conforti et al., 2007).
For Exon7 SMN-NLS NMNAT1-FLAG: 5-ATCCCAAGCTTAAC-
TTCTCCCCATGGGTTTCAGACAAAATCAAAAAGAAGGAAGGTGC-
TCACATTCCTTAAATGACTCATCCAAGAAG-3.
For GAP43 MEM-NLS NMNAT1-FLAG: 5-ATCCCAAGCTT-
AACTTCTCCCCATGCTGTGCTGTATGAGAAGAACCAAACAGGTT-
GAAAAGAATGATGAGGACCAAAAGATCGACTCATCCAAGAAG-3.
For AICD-NLS NMNAT1-FLAG (subsequently named Ax-NMNAT1):
5-ATCCCAAGCTTAACTTCTCCCCATGGGATATGAGAATCCAACTTA-
CAAGTTCTTTGAGCAAATGCAGAACGACTCATCCAAGAAG-3.
NMNAT1-FLAG cDNA was prepared as for NLS NMNAT1-FLAG
using WldS cDNA as template.
FLAG-tagged constructs expressing the first N70 aa of Ube4b without
(N70-FLAG) and with (N70-Wld18-FLAG) the 18 unique amino acids
(Wld18) were amplified fromWldS cDNA contained in pHAPr-1 vec-
tor (Mack et al., 2001). Act F (5-ACTTCGGCTCACAGCGCG-3), an-
nealing within the-actin promoter, was used as forward primer and the
following sequences were used for reverse primers (BamHI cloning site
underlined, stop codon in bold, FLAG tag italicized):
For N70-FLAG: 5-CGCGGATCCTCACTTGTCATCGTCGTCCT-
TGTAATCTGCTGCACCTATGGGGG-3.
For N70-Wld18-FLAG: 5-CGCGGATCCTCACTTGTCATCGT-
CGTCCTTGTAATCGGGGAGAGTTGGTGGTGT-3.
The FLAG-tagged construct expressing the 18 unique aa followed by the
full-lengthNMNAT1 cDNA (18-NMNAT1-FLAG)was amplified from the
same template using the following forward primer (5 HindIII cloning tag
underlined, start codon in bold) and WldS-FLAG reverse (Wilbrey et al.,
2008): 5-GCCGAAGCTTAAGAAAGCGATGGACAACATCGCTGTC-
3.TheWldS-FLAGconstructwas reportedpreviously (Wilbreyet al., 2008).
All the PCR products were double digested with BamHI and HindIII
restriction enzymes and cloned into pHAPr-1 vector downstream of
the -actin promoter for expression in neurons and other cell types as
described by Mack et al. (2001). Ax-NMNAT1-mCherry was produced
by PCR amplification using BamHI- and HindIII-tagged primers and
subcloned in-frame to the mCherry sequence into pcDNA3 vector. The
sequence of each construct was then verified. For transfection, plasmids
were prepared using the EndoFree Plasmid Maxi-kit (Qiagen).
The Ax-NMNAT1 construct within pHAPr-1 was digested with EcoRI/
NdeI and the resulting 5.7 kbp linear DNA was used for pronuclear micro-
injection into an F1 C57BL/CBA strain by the in-house Gene Targeting
Facility of the Babraham Institute. Founders were crossed to homozygous
YFP-H mice (Feng et al., 2000) and their progeny genotyped by Southern
blotting. For this study, we also used double-heterozygous native WldS/
YFP-Hmice, triple-heterozygous tg-WldS/WldS/YFP-Hmice, homozygous
natural WldS mice, NMNAT1-overexpressing/YFP-H mice (line 7104)
(Conforti et al., 2007), double-hemizygousNLSWldS/YFP-Hmice (line 2
and 3) (Beirowski et al., 2009), and double-hemizygousN16WldS/YFP-H
mice (line 1) (Conforti et al., 2009). Triple-heterozygous tg-WldS/WldS/
YFP-H mice express levels of WldS protein similar to that in homozygous
natural WldS mice and display a similarly retarded time course of axon
degeneration (Beirowski et al., 2005).
All animal work was performed in accordance with the Animals (Sci-
entific Procedures) Act (1986) under Project Licenses PPL 80/1778 and
PPL 80/2254.
Genotyping. For mouse genotyping by Southern blotting, genomic
DNA extracts were digested by BamHI and HindIII (Invitrogen) at 37°C
overnight, and run on 0.8% agarose gels in TBE. The gels were denatured
in 0.4 M NaOH with two changes at 30 min intervals. The gel was South-
ern blotted overnight onto Hybond XL (GE Healthcare) in 0.4 M NaOH,
and hybridized with a probe of radioactive WldS cDNA. Posthybridiza-
tion washes were performed at a stringency of 0.1 SSC, 0.1% SDS.
Radioactive filters were exposed to x-ray film for 24 h or longer at80°C.
Cell culture. Culture and transfection of hippocampal neurons were
described previously (Wilbrey et al., 2008) and dorsal root ganglion
(DRG) neurons were processed in a similar way. In brief, dissociated
neurons from E14.5–E16.5 embryos were plated on coated glass cover-
slips or IBIDI -dishes, and transfected at DIV 3–5. Neurons were cut
with a scalpel to test axonal preservation 24 h after transfection or fixed
with 4% paraformaldehyde (PFA) in 0.1 M PBS 20–48 h later for immu-
nofluorescence and high-resolution confocal imaging. DRG explants
from E14.5–E16.5 embryos were dissected and plated as described by
Conforti et al. (2007). Aphidicolin (2 M) was added to dissociated and
explant DRG cultures to reduce the number of non-neuronal cells. Neu-
rites were axotomizedwith a scalpel at DIV 7 and phase-contrast pictures
of the same field were taken immediately (0 d) and 1, 3, and 6 d after
cutting. An Olympus IX81 microscope coupled to a PC running SIS
imaging software was used for image acquisition. A second cut was per-
formed at the same location 3 d after the first axotomy to avoid regener-
ation and DRGs were rinsed with fresh medium. Explants were collected
at DIV 13 for Western blot analysis.
Treatments with microtubule destabilizing agent. Vincristine (Sigma)
and nocodazole (Calbiochem) were diluted in DMSO and added to the
cultures at the final concentrations of 0.04 M, and 5 or 20 g/ml, re-
spectively, at the indicated times (see Fig. 7). DMSOwas used for control
cultures. Medium with fresh drugs was replaced every 24 h.
Assessment of in vivo axonal preservation. We used expression of the
YFP-H transgene for longitudinal imaging of YFP-labeled axons in sciatic
and tibial nerve, an established method for morphological assessment of
axonal preservation (Feng et al., 2000; Beirowski et al., 2004; Beirowski et al.,
2005; Conforti et al., 2009). Mice were anesthetized with isoflurane (Abbot
Animal Health) and subcutaneous injection of 2.5 g of buprenorphine
hydrochloride (Vetergesic, Alstoe Lt. AnimalHeath), and unilateral sciatic
nerve lesion was performed as described by Beirowski et al. (2009); the
contralateral side served as control. A 5 mm segment of sciatic nerve was
removed to prevent regeneration complicating the analysis of the distal
stump at longer lesion durations (14–35 d). Seven, fourteen, and thirty-
five days after surgery, mice were humanely killed and 1.5-cm-long
nerve distal stumps removed. The lesion site was inspected to confirm
that the proximal anddistal stumps had remained separated.Nerveswere
immersion-fixed in 4%PFA and 0.1 M PBS and processed for imaging on
aZeiss LSM510Meta confocal system as previously described (Beirowski
et al., 2004). Confocal z-stack series from longitudinally embedded nerve
were taken using a 20magnification objective, and z-projections were
generated for final presentation using algorithms from Zeiss LSM Soft-
ware Release 3.2.We quantified unfragmented YFP-positive axons in the
distal tibial nerve as a percentage of the mean number of YFP-positive
axons in uninjured preparation.
Assessment of in vitro axonal preservation. For transection experiments
on DRG explant cultures (see Fig. 4), phase-contrast images (20mag-
nification) of axotomized neurites were taken at 0, 1, 3, and 6 d. Bright-
ness and contrast were adjusted for an entire 0.3 mm 0.3 mm square
from each image using Adobe Photoshop to obtain similar background
intensities. Images were further processed using NIH ImageJ software
similar to the method described by Sasaki et al. (2009a). Accordingly,
images were binarized so that axons appear black. The degree of axonal
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continuitywas scored using the Particle Analyzer tool with size (in square
pixels) set at 100 to infinity. This algorithmmeasures the number of black
pixels in continuous axons and excludes axons with high degree of frag-
mentation. We normalized it for the total number for black pixels (total
axonal area) in the field to obtain a protection index (PI) value. Typically
an image of intact axons has a PI value around 1 and an image of frag-
mented axons has a PI value around 0.5. A PI around 0 occurs when
axons detach from the dish (such fields where excluded from the quan-
tification) or when only debris remains that is smaller than theminimum
set size (100 square pixels). Results from C57BL/6 embryos and Ax-
NMNAT1-negative embryo littermates were grouped together as wild-
type (WT) control. For each genotype, images from 3–10 dishes were
quantified (2–3 fields/dish). DRG explant cultures in presence of micro-
tubule destabilizing agents (see Fig. 7) were cut and imaged in the same
way. Axonal protection of dissociatedDRGneuronswas tested by cutting
single neurons that coexpressed EGFP and Ax-NMNAT1-mCherry.
Neurons were imaged with an Olympus IX81 microscope, and only the
ones coexpressing green and red fluorescence were selected to be axoto-
mized. The percentage of axons that did not develop extensive varicosi-
ties or fragmentation 48 h after cut was quantified (SD), in presence or
absence ofmicrotubule-destabilizing agents (see Fig. 7) (10–20 neurons/
condition, 2–4 dishes tested).
NMNAT enzyme activity assay. Brains were divided in half sagittally,
snap frozen in liquid nitrogen, and kept at80°C. One hemisphere was
used for NMNAT activity assay and the other was used for Western blot
analysis. NMNAT assay was performed as described previously (Mack et
al., 2001) with minor modifications. Tissue was Ultra-Turrax homoge-
nized in 5 volumes of ice-cold buffer [50 mM HEPES, pH 7.4, 0.5 mM
EDTA, 1 mM MgCl2, 1 mM DTT, and protease inhibitor (Mini-protean
EDTA-free, Roche)]. NMNAT activity assay was performed at 37°C in a
0.15 ml reaction mixture containing 50 mM Tris-HCl, pH 7.5, 5 mM
nicotinamidemononucleotide (NMN), 3mMATP, 20mMMgCl2, 20mM
NaF, and an appropriate aliquot of brain homogenate. The reaction was
started by adding 5 mM NMN and stopped by the addition of a half-
volume of ice-cold 1.2 M HClO4. After 10 min at 0°C, the mixture was
centrifuged and 100l of supernatant was neutralized by the addition of
26 l of 0.8 M K2CO3. NMNAT activity was calculated by reverse-phase
HPLC identification (C18 column) and quantification of the product
(NAD). One unit of enzyme was defined as the amount capable of
producing 1 mol of NAD per minute at 37°C. Specific NMNAT ac-
tivity was obtained by normalization with protein content calculated by
Bradford assay (Bio-Rad).
Assessment of in vivo preservation of neuromuscular junctions. Mice
were killed by cervical dislocation and previous section of the sciatic
nerve was verified by reexposing the wound in the thigh. Tibial nerve–
flexor digitorumbrevis (FDB) and lumbrical preparationswere dissected
in Babraham and bathed in oxygenated mammalian physiological saline
(137mMNaCl, 5mMKCl, 2mMCaCl2, 1mMMgCl2, 5.6mM glucose, and
5 mM HEPES, pH 7.2–7.4, equilibrated with 100% oxygen). In some
experiments, preparations were dissected then couriered in cold (4°C)
physiological saline to Edinburgh, where electrophysiological recordings
were made later the same day as described by Mack et al. (2001). Minia-
ture endplate potentials (MEPPs) and evoked synaptic response (EPPs)
to tibial nerve stimulation were recorded and quantified in FDBmuscles
from 6 d lesioned age-matched WldS homozygotes and 3 Ax-NMNAT1
hemizygotes from line 2 for each of these tests. Contralateral muscles
were used as uncut controls. For morphological quantification of neuro-
muscular junctions (NMJs), preparations of FDB and lumbrical muscles
from age-matched, 6 d lesioned Ax-NMNAT1, WldS, NLS WldS,
NMNAT1, and WT mice were retained in Babraham, and pinned to a
Sylgard-lined dish. Recycling synaptic vesicles of motor nerve terminals
were stained using AM1-44 (8 M) (Biotium) and acetylcholine recep-
tors were stained with tetramethylrhodamine isothiocyanate conjugates
of -bungarotoxin (TRITC--BTX) (5 g/ml) (Biotium) in depolariz-
ing saline [50mMKCl/75mMNaCl substitution, as described byRibches-
ter et al. (1994)]. AM1-44 is a fixable form of styryl-dye FM1-43, a widely
used vital label of NMJs, and indicates functional synaptic transmission.
Muscles were fixed in 4% PFA, 0.1 M PBS for 20 min and mounted on
conventional glass slides in Vectashield mounting medium for subse-
quent analysis. For endplate occupancy, we assessed alignment of the
presynaptic AM1-44 vital marker and the postsynaptic TRITC--BTX
staining using an IX81 Olympus fluorescence microscope. Muscle prep-
arations were imaged using a Zeiss LSM 510 Meta confocal system in
Multi-trackmode to avoid fluorescence bleed-through, and z-series were
merged using algorithms from Zeiss LSM Software Release 3.2.
Immunohistochemistry and immunocytochemistry. For immunofluores-
cence detection of axonally targeted NMNAT1 in brains, Ax-NMNAT1
micewere intracardially perfusedwith 4%PFA in 0.1MPBS andbrainswere
postfixed for 24 h, cryopreserved for 3 d, embedded in OCT medium, and
subsequently sectioned using a Leica cryostat. Perfused brains of transgenic
mice expressing FLAG-tagged SOD1 (kind gift from Prof. Yasuhiro Wa-
tanabe, Tottori University, Tottori, Japan) (Watanabe et al., 2005) were
cryosectioned and processed as positive controls. Sections (20 m) were
mounted onto SuperFrost Plus glass slides (VWR) and incubated overnight
in citrate buffer, pH6.0, at 50°C for antigen retrieval. After permeabilization
with 0.1% Triton X-100 plus 0.05 M NH4Cl in 0.05 M TBS for 10 min, the
sections were rinsed in fresh TBS, immunoblocked with 5% bovine serum
albumin (Sigma) in TBS for 1 h, and incubated overnight at 4°C in primary
antibody solution (Sigma F1804mouse anti-FLAG antibody, 1:500 in 0.8%
bovine serum albumin in TBS). After extensive washes, the secondary anti-
body solution (Alexa568-goat anti-mouse, 1:200 inTBS)was applied for 1 h
at room temperature and slices were rinsed in TBS and dH2O.
For immunofluorescence of transfected hippocampal neurons, cells were
fixed in 4%PFA, 0.1MPBS for 10min, permeabilizedwith 1%TritonX-100
for10min,blocked[5%NGS(Sigma) inPBS,1h], and immunostainedwith
mouse anti-FLAG antibody (1:2000) (Sigma F3165) overnight followed by
1 h incubation with secondary Alexa568-goat anti-rabbit antibody (1:200)
(Invitrogen), both diluted in 5% NGS in PBS. In hippocampal cultures,
dendrites were counterstained with chicken anti-MAP-2 antibody
(1:30,000) (AbCam) and secondary Alexa647-goat anti-chicken antibody
(Invitrogen). Proximal axons were stained with rabbit anti-Ankyrin G anti-
body (1:400) (Santa Cruz Biotechnology) and secondary Alexa488-goat
anti-rabbit antibody (Invitrogen).
Cryosections and cell culture samples were mounted in Vectashield
mounting medium containing DAPI for nuclear counterstaining (Vector
Laboratories) and imaged using the Zeiss LSM510MetaConfocal system in
Multi-track mode to avoid fluorescence bleed-through. Z-series were
merged using projection algorithms from Zeiss LSM Software Release 3.2.
Western blotting and subcellular fractionation.Western blotting of total
brain homogenates (see Fig. 2)was performed as described byConforti et
al. (2007) with minor modifications. Brains were homogenized in 5 vol-
umes of RIPA buffer, high-speed supernatant was further centrifuged at
2000 g for 5 min, and concentrated brain homogenate was loaded for
SDS-PAGE and blotted to PVDF membranes. After overnight blocking,
the Western blot was probed with anti-NMNAT1 antibody 183 (1:250)
(Conforti et al., 2000) or mouse anti-FLAG antibody (1:1000) (Sigma
F1804) for 3 h at room temperature. This was followed by incubation
with the appropriate IgG-HRP-conjugated secondary antibodies. Mouse
monoclonal anti--actin (Abcam)was used as loading control. Cell bod-
ies and neurites of 30 DRGs were harvested, resuspended in 150 mM
NaCl, 50 mM Tris/HCl, and 10% SDS, pH 8.0, boiled, and loaded in one
well of SDS-polyacrylamide gel for immunoblotting as above. Brain nu-
clear and postnuclear fractions (see Fig. 5) were obtained as described by
Beirowski et al. (2009).More extensive subcellular fractionation (see Fig.
8) was performed as follows. Brains were homogenized in 5 volumes of
buffer (300 mM sucrose, 10 mMHEPES, 5 mM EDTA, protease inhibitor,
pH 7.4) and centrifuged at increasing speed as described by Beirowski et
al. (2009) to obtain the nuclear, postnuclear, andmitochondria-enriched
fractions. All pellets were resuspended in homogenization buffer con-
taining 0.5 mM NaCl. Vesicle fractions were obtained from the superna-
tant of the mitochondria-enriched fraction as described previously
(Morfini et al., 2001; Lazarov et al., 2005): V0 [40,000 g (max) for 40
min at 4°C], V1 [120,000 g (max) for 40 min at 4°C], V2 [260,000 g
(max) for 2 h at 4°C]. The supernatant of the last spin yielded the cytosol.
Purity was validated by probing with the following antibodies: mouse
anti-calnexin, mouse anti-adaptin  (both from BD Biosciences), rabbit
anti-Sp1 (SantaCruz),mouse anti-p38 synaptophysin (SNPH) (DAKO),
and rabbit anti-prohibitin (Abcam), and (variant)WldS was detected by
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antibody Wld18 (Samsam et al., 2003), all followed by the appropriate
secondary IgG-HRP-conjugated antibody. Protein concentration was
measured by Bradford assay (Bio-Rad) and similar amount of protein
from all fractions was used for immunoblots.
Time-lapse imaging. Transfected dissociated DRG and hippocampal
neurons were imaged as described previously (Gilley and Coleman,
2010) within 24 h after transfection, and immediately after treatment
withMitoTracker Green FM (Invitrogen), as permanufacturer protocol.
Wide-field epifluorescence images were captured at 1 Hz. After acquisi-
tion dishes were moved to a Zeiss LSM510 confocal and stacks acquired.
Statistical analysis. Data are presented as mean SD. Student t test was
performed for statistical analysis: group comparisonwas considered not sta-
tistically significant (NS) if p 0.05, or highly significant (**) if p	 0.01.
Results
A C-terminal peptide from the amyloid precursor protein can
target NMNAT1 to axons in vitro
We hypothesized that N70 delivers NMNAT1, which is normally
a nuclear protein (Schweiger et al., 2001; Berger et al., 2005), to
Figure 1. Confocal z-projections showing the targeting of NMNAT1 to axons. A, Immunostained hippocampal neurons transfected with FLAG-tagged native NMNAT1 (NMNAT1-FLAG), FLAG-
tagged NMNAT1 with disrupted nuclear localization (NLS NMNAT1-FLAG), and FLAG-tagged NLS NMNAT1 N-terminally fused to a peptide from exon 7 of SMN protein (Exon7 SMN-NLS
NMNAT1-FLAG) or to a peptide from the AICD of APP (AICD-NLS NMNAT1-FLAG). Anti-FLAG immunocytochemistry labeled the overexpressed NMNAT1 variants (red). On the right, 20 images
showthatAICD-NLSNMNAT1-FLAG redistributes todistal axonsmost efficiently. Cell body insets are shownat 63magnificationon the left. Anti-ankyrinG identifiedproximal axons (green), and
anti-MAP-2 marked dendrites (pink); nuclei were counterstained with DAPI (blue). Superimposed images of overexpressed NMNAT1 variants and ankyrin G are shown in the merge panel. Arrows
point to axons. B, The AICD-NLS NMNAT1-FLAG construct was named Ax-NMNAT1 (axonally targeted NMNAT1) and selected for the generation of transgenic mice. In the N-terminal axonal
targeting sequence, evolutionarily conserved amino acids are highlighted in yellow.
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axons and synapses inWldSmice, where it prolongs their survival
after injury. In transfected hippocampal cultures, we detected
N70 exclusively outside the nucleus, and it was abundant in neu-
rites. In contrast, we found overexpressed NMNAT1 only in the
nucleus (supplemental Fig. 1, available at www.jneurosci.org as
supplemental material). This is in line with previous reports
showing presence of full-length Ube4b in the cytoplasm and ax-
ons in vivo (Mack et al., 2001; Fang et al., 2005). The unique 18 aa
sequence of WldS (Wld18) did not affect distribution (supple-
mental Fig. 1, available at www.jneurosci.org as supplemental
material). Next, we fused several reported axonal targeting peptides
N-terminally to NMNAT1 that had been mutated in its nuclear lo-
calization sequence (NLS NMNAT1). The aim was to identify an
axonal targeting tag that would mimic the N70-mediated targeting
ofNMNAT1.We tested the peptidesGFPQNQKEGRCS fromexon
7ofthesurvivalmotorprotein(SMN)(Zhangetal.,2003), thecytoplas-
mic targeting sequence (MEM) MLCCMRRTKQVEKNDEDQKI
fromgrowth cone-associated protein (GAP-43) (Zuber et al., 1989),
andGYENPTYKFFEQMQNfromamyloidprecursorprotein intra-
cellular domain (AICD) (Satpute-Krishnan et al., 2006). For com-
parative immunofluorescence all constructs were also FLAG tagged
at their C terminus.
The efficiency of these peptides in targeting NLS NMNAT1
to axons was compared in transfected hippocampal cultures. Ax-
ons were identified by morphological criteria and by immuno-
staining with the proximal axonal marker anti-ankyrin G
(Kordeli et al., 1995). Only neurons with low-to-medium level of
immunosignal were analyzed to avoid mislocalization due to
overexpression. The 15-aa-long AICD sequence of APP (AICD-
NLS NMNAT1-FLAG) was the most effective in redistributing
NLS NMNAT1 to the axon, especially to distal regions (Fig.
1A). Although a little AICD-NLS NMNAT1-FLAG was also
present in MAP-2-positive dendrites, significantly more diffuse
or dendritic staining was visible without targeting (NLS
NMNAT1-FLAG) or in presence of the targeting sequence from
exon 7 of SMN protein (Exon7 SMN-NLS NMNAT1-FLAG).
TheMEM sequence of GAP-43 caused toxicity and was therefore
not examined further. Thus, the AICD-NLS NMNAT1-FLAG
construct (Fig. 1B) was selected for microinjection to produce
axonally targeted NMNAT1 (Ax-NMNAT1) mice.
Expression of Ax-NMNAT1 transgene at low doses
We established six Ax-NMNAT1 hemizygous transgenic lines
from seven founders (lines 1–4, 6–7) by breeding to YFP-Hmice
(Feng et al., 2000) for convenient assessment ofWallerian degen-
eration (Beirowski et al., 2004). Western blotting of brain ho-
mogenates revealed low levels of axonally targeted NMNAT1
protein in Ax-NMNAT1 mice using anti-FLAG antibody, that
increased approximately twofold in line 2 when bred to homozy-
gosity (Fig. 2A). Anti-NMNAT1 antibody 183 (Conforti et al.,
2000) demonstrated that levels of Ax-NMNAT1 were substan-
tially lower than WldS in WldS heterozygotes and NMNAT1 in
NMNAT1-overexpressing transgenic mice (Conforti et al.,
2007), respectively (Fig. 2B). In hemizygous line 1 Ax-NMNAT1
mice protein expression was below the detection limit, and only
faintly visible in concentrated DRG samples from homozygous
mice (see Fig. 4C). Because enzymatic NMNAT activity is essen-
tial for WldS neuroprotection (Araki et al., 2004; Jia et al., 2007;
Conforti et al., 2009; Sasaki et al., 2009a) and measurements of
NMNAT enzyme activity also allow quantitative assessment of
transgenic protein levels (Conforti et al., 2007; Beirowski et al.,
2009), we assayed total NMNAT activity in brains from Ax-
NMNAT1mice. Line 1 samples showed activity similar towild-type
(WT) littermates, further indicating that transgeneexpression in this
line is very low. Activity in line 2 was only slightly increased and
remained significantly lower than that in WldS heterozygotes (Fig.
2C). This confirmed that the fusionproteinwas enzymatically active
and the specific values of NMNAT enzyme activity correlate with
protein expression levels as detected by Western blotting. The ab-
sence of specific immunofluorescence on brain cryosections (sup-
plemental Fig. 2, available at www.jneurosci.org as supplemental
material) further confirms the lackofhigh transgeneexpression.The
efficacy of the FLAG antibody was validated using controls from
FLAG-tagged wild-type (WF) and frame-shifted (DF) superoxide
dismutase transgenic mice (Watanabe et al., 2005) (supplemental
Fig. 2, available at www.jneurosci.org as supplemental material).
Figure 2. Axonally targeted NMNAT1 levels in brains of Ax-NMNAT1mice from line 1 and 2.
A, Western blotting of Ax-NMNAT1 line 2 mouse brain homogenates showing approximately
twofoldhigher expression level of Ax-NMNAT1protein in homozygotes than inhemizygotes, by
anti-FLAG antibody detection (top) and anti-NMNAT1 antibody detection (bottom). B, Repre-
sentative anti-NMNAT1 (antibody 183) Western blot of total brain homogenates of Ax-
NMNAT1 mice. Anti-NMNAT1 antibody 183 detects both NMNAT1 and Wld S. Axonally
targeted NMNAT1 is 23 aa longer than murine native NMNAT1 and therefore migrates
more slowly on SDS-polyacrylamide gel. Transfected HEK lysates indicate the molecular
size of NMNAT1 and Ax-NMNAT1. Ax-NMNAT1-transfected HEK lysate is 10-fold diluted;
thus, its loading control band (-actin) is not visible at this exposure time. In A and B, #
indicates nonspecific band. C, Confirmation that axonally targeted NMNAT1 is enzymati-
cally active in brain homogenates and that activity levels correlate with protein levels.
Levels of NMNAT specific enzyme activity are higher in Ax-NMNAT1 mice from line 2 than
in negative control littermates (WT). NMNAT enzyme activity of Ax-NMNAT1 mice from
line 1 is similar to theWT one. Both Ax-NMNAT1 lines show levels lower than the ones from
all the other strains. **p
 0.0037.
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Robust axon protection in vivo and
in vitro
An amount of WldS protein comparable
to this level of axonally targetedNMNAT1
would be unlikely to grant axonal protec-
tion in WldS transgenics or at best have
only a weak effect (Mack et al., 2001).
Strikingly however, both Ax-NMNAT1
lines showed robust axonal protection, as
did all four other Ax-NMNAT1 lines,
which expressed the fusion protein at lev-
els similar to or lower than line 2 (data not
shown). Seven and fourteen days after
transection,most axons were still intact in
the distal stump of the sciatic nerve as as-
sessed by YFP longitudinal imaging (Fig.
3). In clear contrast, all axons from WT
and NMNAT1-overexpressing mice were
completely fragmented as early as 3 d
after nerve lesion as previously reported
(Beirowski et al., 2004; Conforti et al.,
2007), despite the higher transgene ex-
pression level in the latter.
Next, we examined axonal preserva-
tion 35 d after axotomy, a time point at
which native WldS no longer preserves
axons. Continuous axons were consis-
tently present in distal stumps of sciatic
nerve from Ax-NMNAT1 L2 mice and in
tibial nerves of both Ax-NMNAT1 lines,
similar to the preservation by extranuclear
WldS (NLSWldS) (Fig. 3 and supplemen-
tal Fig. 3, available at www.jneurosci.org
as supplemental material). Regeneration
was ruled out in the distal stump by imag-
ing the cut site, where all the intact axons
originated from end bulbs (likely result-
ing from continued retrograde axonal
transport), which mark the lesion site
(supplemental Fig. 3, available at www.
jneurosci.org as supplemental material).
Moreover, degeneration in Ax-NMNAT1
nerves was clearly dose-dependent. Ac-
cordingly, in Ax-NMNAT1 line 3, which
showed transgene instability, the degree
of axonal protection correlated to protein
expression level in eachmouse of the same
progeny (supplemental Fig. 4, available
at www.jneurosci.org as supplemental
material).
The comparison of Ax-NMNAT1 and
NLS WldS lines with similar transgene
expression levels indicated a stronger axon sparing activity of
Ax-NMNAT1.Mice from line 1 of theNLSWldS strain express
undetectable level of transgenic protein (Beirowski et al., 2009),
analogous to Ax-NMNAT1 line 1, but their tibial nerve axons
show clearlymore extensive fragmentation 14 d after lesion (sup-
plemental Fig. 5, available at www.jneurosci.org as supplemental
material).
Thus, Ax-NMNAT1 protects axons more robustly than WldS,
even when expressed at substantially lower levels. Moreover, these
data indicate that Ax-NMNAT1 confers higher axoprotective po-
tency than extranuclearWldS in vivo.
The efficacy was also evident in vitro using neurons from Ax-
NMNAT1 mice (Fig. 4). We evaluated neurite survival up to 6 d
after cutting in cultured DRG explants from hemizygous em-
bryos of Ax-NMNAT1 line 1 and 2 both by identification of
beading and fragmentation (Fig. 4A) and by quantitative
software-based analysis of axonal continuity (Fig. 4B). For this
purpose, we developed a formula that quantifies the degree of
axonal protection, which we termed PI. PI calculates the area
occupied by continuous axons versus the total axonal area in each
imaged field and is near to 1 when all axons are intact. As frag-
mentation progresses after axotomy PI decreases, dropping to
Figure 3. Comparison of delay of Wallerian degeneration in Ax-NMNAT1 mice and in mice with the indicated genotypes
expressing YFP in a representative subset of neurons. Longitudinal imaging (confocal z-projections) of sciatic and tibial nerves 7,
14, and 35 d after transection, and quantification of percentages of intact axons in distal tibial nerves 35 d after lesion. Nerves
from NMNAT1-overexpressing mice (TgNMNAT1) fragment with a time course similar to WT nerves, whereas 35 d lesioned
nerves from hemizygous Ax-NMNAT1 mice still show intact axons. Thirty-five days after axotomy, the number of unfrag-
mented axons in Ax-NMNAT1 samples is significantly higher than the one in Wld S samples and similar to the one inNLS
Wld S samples. (**p
 0.003, one-sample t test; NS: p
 0.399).
13296 • J. Neurosci., October 6, 2010 • 30(40):13291–13304 Babetto et al. • Targeting NMNAT1 to Axons Transforms Its Potency
levels around 0.5 within the first 24 h for WT or DRGs from
homozygous NMNAT1-overexpressing transgenic mice. By
contrast, Ax-NMNAT1 neurites from both lines remained un-
fragmented for at least 6 d after cutting, similar to WldS and
NLS WldS neurites, with a PI constantly close to 1 (Fig. 4B).
We confirmed high NMNAT1 expression in DRGs from
NMNAT1 homozygotes, whereas Ax-NMNAT1 expression
was low in homozygous cultures from line 2 (Fig. 4C). Re-
markably, similar to the in vivo findings, Ax-NMNAT1 pro-
tein was detectable in Ax-NMNAT1 line 1 DRGs only if
cultured from homozygotes (Fig. 4C), but remained below
detection limit in hemizygous cultures (data not shown).
Thus, whereas overexpressed nuclear NMNAT1 does not pro-
tect axons, axonally targeted NMNAT1 delays Wallerian de-
generation similar to extranuclear WldS in vivo and in vitro,
despite the greatly reduced expression level.
Axonally targeted NMNAT1 localizes
outside the nucleus in vivo at low levels
Because the protective action is deter-
mined by extranuclearWldS (Beirowski et
al., 2009) and is dose dependent (Mack et
al., 2001), we compared extranuclear ex-
pression levels betweenAx-NMNAT1 and
other strains. Commercially available
anti-NMNAT1 antibodies could barely
detect native NMNAT1 in mouse lumbar
spinal cord cryosections (Conforti et al.,
2007). Thus, we based our comparison on
Western blots of fractionated brain ho-
mogenates immunoblotted with antibody
183, which we previously used for suc-
cessful detection of NMNAT1 and WldS
(Conforti et al., 2007).We confirmed that
Ax-NMNAT1 protein is redistributed
outside the nucleus in line 2 samples (Fig.
5), and found levels similar to the ones
from the variant N16 WldS, which does
not confer axon protection (Conforti et
al., 2009).Densitometric quantification of
cytoplasmic levels revealed that axonally
targeted NMNAT1 is expressed 24.4%
lower thanWldS, and96.5% lower than
NLSWldS in the respective strains. Nev-
ertheless, axonal preservation in Ax-
NMNAT1 line 2 mice is greater than in
WldS and similar to NLS WldS mice
from line 3 (Fig. 3), suggesting that axonal
delivery of NMNAT1 markedly increases
its efficacy.
Axonally oriented NMNAT1 preserves
motor nerve terminals robustly in
young and adult mice
Motor nerve terminal preservation de-
creases with age in homozygous sponta-
neous mutant and transgenic WldS mice,
and is absent in WldS mice older than 3
months (Gillingwater et al., 2002). How-
ever, extranuclearWldS can protect NMJs
efficiently in aged mice (Beirowski et al.,
2009). Thus, as a stringent test, we mea-
sured the efficacy of axonally targeted
NMNAT1 at motor nerve terminals.
WldS would not be expected to delay denervation of NMJs at
these expression levels, as motor nerve terminals in WldS het-
erozygotes are not preserved following axotomy even at 1–2
months of age (Wong et al., 2009). First we imaged synaptic
vesicle recycling (Fig. 6A) and recorded evoked action potentials
by intracellular recordings in deep lumbrical and FDBmuscles of
2-month-old hemizygous Ax-NMNAT1 mice from line 2 (Fig.
6B). Both the morphological and the functional evaluation re-
vealed a robust degree of NMJ preservation 6 d after axotomy. In
Ax-NMNAT1 FDB and lumbrical muscles respectively, 69% and
67% ofmotor endplates were fully labeled by AM1-44 vital stain-
ing, showing complete innervation with synaptic vesicles recy-
cling activity in 100% of their area 6 d after axotomy. In contrast,
inWldS FDB and lumbricalmuscles, only 38%and 42%ofmotor
endplates retained full innervation 6 d after axotomy, in line with
previous data (Gillingwater et al., 2002). In physiological record-
Figure 4. Neurite preservation after axotomy in DRG explant cultures from hemizygous Ax-NMNAT1 embryos. A, Phase-
contrast 0.3mm 0.3mm images of the same field at the time of transection, and 1, 3, and 6 d after. Neurites from Ax-NMNAT1
explant cultures remain unfragmented for at least 6 d similar to neurites from spontaneous mutant Wld S and transgenicNLS
Wld S explant cultures. Neurites from homozygous NMNAT1-overexpressing (TgNMNAT1) embryos fragment within the first 24 h.
Scale bar, 0.1mm.B, Quantification of neurite continuity by assessment of the PI plotted against timeafter cutting.C,Western blot
probed with anti-NMNAT1 antibody 183, showing the respective transgenic protein expression in homozygous DRGs explant
cultures.-Actin is the loading control.
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ings, 62.2% of fibers showed nerve evoked endplate potentials
(EPPs). The extent of theNMJ preservationmeasured physiolog-
ically in this way was at least as strong as that of age-matched
WldS homozygotes (Fig. 6B and supplemental Fig. 5, available at
www.jneurosci.org as supplemental material). Next, we made
similar measurements in 6 d lesioned hemizygous Ax-NMNAT1
mice older than 6 months (Fig. 6A,C). As expected age-matched
WldS homozygotes showed almost complete denervation and
neither spontaneous nor evoked action potentials. Remarkably,
muscles from these older Ax-NMNAT1mice still recycled synap-
tic vesicles and responded to electrophysiological stimulation
with evoked EPPs (average of 35.56% of fibers per muscle). An
additional 18.87% of fibers per muscle did not respond to nerve
stimulation but did show evidence of spontaneous miniature end-
plate potentials (MEPPs). Morphological preservation of nerve ter-
minals was also evident in axotomized adult Ax-NMNAT1 mice
from line 1 by imaging of YFP-labeled motor nerve terminals (sup-
plemental Fig. 6, available at www.jneurosci.org as supplemental
material). Thus, axonally targetedNMNAT1 confers enhanced effi-
cacy for NMJ preservation. The level of synaptic protection appears
similar to that reported in our previous study of transgenic mice in
which full-length WldS protein was targeted away from its normal
nuclear localization (Beirowski et al., 2009).
Delivery of NMNAT1 to axons is necessary for
axon protection
To test whether axonal delivery of NMNAT activity is necessary
for axon protection as well as sufficient, we examined the effect of
blocking axonal delivery of the Ax-NMNAT1 protein. In initial
experiments, we added a dileucine (LL) dendrite targeting pep-
tide from Shal K channels—FETQHHHLLHCLEKTT (Rivera
et al., 2003)—but found that this was not sufficient to achieve
complete exclusion from the axonal compartment in hippocam-
pal and DRG neurons (data not shown). Considering that only
very low levels of Ax-NMNAT1 are needed to protect axons (e.g.,
in line 1 hemizygotes), it is important to block axonal delivery
more completely to test this hypothesis.
Therefore we inhibited entry of Ax-NMNAT1 into axons
pharmacologically immediately after it was expressed. DRG neu-
rons were transfected with Ax-NMNAT1-mCherry and at the
same time treated with high concentration of vincristine (0.04
M) or nocodazole (20 g/ml), to achieve fast and complete
disruption of axonal transport. Ax-NMNAT1-mCherry protein
was expressed in presence of drugs, but restricted to the soma and
proximal neurites (supplemental Fig. 8, available at www.
jneurosci.org as supplemental material). DRGs were axotomized
24 h later (Fig. 7Aii,Aiv,Bii,Biv). When axonal transport was
blocked before Ax-NMNAT1-mCherry protein was expressed,
axonal preservation after axotomy was greatly reduced. In con-
trast, axonal sparing was robust if drugs were applied 24 h after
transfection, at the time of cut, allowing time for prior synthesis
and axonal targeting of some Ax-NMNAT1 protein (Fig. 7A–C).
Only 5%and 19%of axons remained free of extensive varicosities
or did not fragment 48 h after cut when microtubules were de-
stabilized early by nocodazole and vincristine, respectively (Fig.
7Cii,Civ), compared to 69% of axons preserved in absence of
drugs. If microtubules were disrupted at the time of axotomy,
24 h after Ax-NMNAT1 expression and axonal delivery, axo-
tomized neurites were preserved as strongly as in absence of
drugs (Fig. 7Ci,Ciii). Thus, preventing axonal NMNAT1 entry
abolishes the protective capacity.
Although the drug treatment induces some axonal varicosities
(supplemental Fig. 8, available at www.jneurosci.org as supplemen-
tal material), a general neuronal intoxication is not responsible for
theneuritedegenerationabovebecauseAx-NMNAT1canprotect in
presence of vincristine and nocodazole, if drugs are applied at the
timeof axotomy.Asa further control for this,weappliednocodazole
at a lower concentration (5g/ml), obtaining similar results, with a
reductionof axonal survival to 29%whennocodazolewas applied at
the time of transfection (Fig. 7C). The slightly higher survival com-
pared to the resultobtainedwith4 timesmoreconcentratednocoda-
zole (20 g/ml) may reflect the lower effectiveness of microtubule
destabilization, and thus the lower efficacy of preventing Ax-
NMNAT1 from entering axons.
WldS explant cultures are known to be resistant to vincristine
toxicity (Conforti et al., 2009), and explants from Ax-NMNAT1
transgenic embryos can be cultured for several days before axo-
tomy, allowing longer time for expression and axonal delivery of
axonally targeted NMNAT1 stably. Thus, we axotomized DRG
explants from Ax-NMNAT1 line 1 homozygotes 6 d after plating
(Fig. 7D). To mimic the conditions of our previous transfected
DRGs, we pretreated the explants with high concentrations of
vincristine or nocodazole for 24 h before neurite transection. Six
days after cut, neurites of Ax-NMNAT1 cultures were still intact
Figure 5. Cytoplasmic redistribution of axonally targeted NMNAT1. Representative
Western blot of nuclear and postnuclear (cytoplasmic) fractions from brains of Ax-
NMNAT1 mice in comparison to native Wld S mice, mice expressing the nonprotective
variant of Wld S lacking the first 16 N-terminal amino acids (N16 Wld S hemi), and mice
expressing the enhanced protective extranuclear variant (NLS Wld S L3 hemi) (n
 4).
Nuclear and cytoplasmic factions, blotted with anti-NMNAT1 antibody 183 (top left and
right), are shown at different exposure times to optimize the visualization of the faint
bands (Ax-NMNAT1, Wld S, and N16Wld S). Sp1 is the loading control for the nuclear
fraction. The densitometry (bottom) shows the intensity of the cytoplasmic bands, nor-
malized to -actin, and is expressed as percentage ofNLS Wld S levels for comparative
analysis. The axonally targeted NMNAT1 protein shows the lowest levels if compared to
Wld S and variants in the other strains. #Nonspecific band.
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maintaining a PI around 0.8, similarly to Ax-NMNAT1 neurites
axotomized in absence of drugs (Fig. 4B). Cultures from
C57BL/6 mice started to fragment 24 h after treatment and were
completely degenerated 6 d after axotomy, with a PI around 0.3
(Fig. 7E,F). This further shows that the longer drug treatment is
also not itself responsible for the neurite degeneration.
Thus, if Ax-NMNAT1-mCherry is allowed to enter axons
freely, it protects them after mechanical injury, and frommicro-
tubule destabilization, including nocodazole toxicity. However,
this protection depends on axonal transport.
Axonally targeted NMNAT1 localizes to
vesicular fractionsandit is cotransported
withmitochondria
The potency of Ax-NMNAT1 in protecting
axons and synapses suggests that axonally
targetedNMNAT1 isdeliveredwithhigh ef-
ficiency to the location where WldS func-
tions. To investigate the specific subcellular
localization of Ax-NMNAT1 protein, we
fractionated brains of Ax-NMNAT1 mice
and (variant) WldS mice by sequential
centrifugation at increasing speeds. We
obtained fractions differently enriched
in organelles as validated by nuclear,
mitochondrial, endoplasmic reticulum
(ER), Golgi, and synaptic vesicle markers
(Fig. 8A). ThedistributionofAx-NMNAT1
and (variant) WldS mostly resembled the
one of synaptic vesicles, with particular
abundance in vesicle fractions V0 and V1,
where also ER and Golgi markers were
present. These proteins, and particularly
Ax-NMNAT1, were abundant also in the
mitochondrial fraction (M) (Fig. 8B). Thus,
we find here that both Ax-NMNAT1 and
WldS are mostly concentrated in a small
membranous compartment in vivo, extend-
ing our previous finding of high levels of
(variant)WldS inmitochondria andmicro-
some fractions and fine granular staining of
extranuclearWldS in sciatic nerve axoplasm
(Beirowski et al., 2009).
Next, we studied this site using an in
vitro imaging approach. Because of the
lack of commercially available, sensitive
antibodies for detection of Ax-NMNAT1
protein,we fusedAx-NMNAT1tomCherry
to observe the fluorescence directly in
transfected hippocampal (Fig. 9A–D) and
dissociated DRG neurons (Fig. 9E–K).
Ax-NMNAT1-mCherry was distributed
in vitro in pleomorphic vesicle-tubular
structures. Similar structureswere also ev-
ident in transfected non-neuronal cells
that are present at low numbers in our
DRG cultures (supplemental Fig. 7, avail-
able at www.jneurosci.org as supplemen-
tal material). Vesicles entered the axons
(Fig. 9B) and, particularly in DRG neu-
rons, were concentrated at the growth
cones (Fig. 9F), where the fluorescence
appeared clearly punctate (Fig. 9G, arrow-
heads). Next, we assessed colocalization
with extranuclear WldS by cotransfection with NLS WldS-
EGFP (Beirowski et al., 2009). NLS WldS-EGFP and Ax-
NMNAT1-mCherry gave a similar vesicle-tubular distribution,
and we noticed partial colocalization in soma (Fig. 9C,D,H) and
particularly in puncta along axons (Fig. 9C,D, I).
Finally, we assessed the identity of these structures by testing
for colocalization (supplemental Fig. 8, available at www.
jneurosci.org as supplemental material) with the same organelle
markers used in the subcellular fractionation experiment (Fig. 8),
along with additional markers of trans-Golgi-network/ER
Figure6. Neuromuscular junctions inAx-NMNAT1mice remain functional for at least 6dafter axotomy in young (2months old)
and adult (6months old)mice.A, Confocal projections showing alignment of vital staining of presynapticmotor nerve terminals
(AM1-44, green) with postsynaptic acetylcholine receptors (TRITC-BTX, red) in lumbrical and FDBmuscles of mice of the indicated
genotype and age. Protection was weak at this time point in young Wld S homozygotes and absent in older (6 months) Wld S
homozygotes but appeared equally strong at both ages in Ax-NMNAT1 mice. B, Intracellular recordings showing evoked (I–III )
and spontaneous (IV ) responses in 4 different FDB muscle fibers from 2-month-old Ax-NMNAT1 hemizygotes (line 2), 6 d after
axotomy. The peaks of evoked action potential are clipped in BI and BII. BI, Response to single tibial nerve stimulus; BII, super-
imposed traces at 1 Hz stimulation showing EPPs with reduced quantal content near the firing threshold;BIII, subthreshold EPPs;
BIV, spontaneous MEPPs recorded in several superimposed sweeps on a free-running time base. C, Intracellular recordings of
synaptic potentials recorded from FDBmuscle fibers of 6-month-old Ax-NMNAT1mice (I, II ) and of 5.5-month-oldWld S homozy-
gotes (III ) 6 d after axotomy, and fromunlesioned contralateral controls (IV ). CI, Superimposed subthreshold EPPs in axotomized
Ax-NMNAT1 FDB muscle. CII, Subthreshold EPPs and a MEPP in axotomized Ax-NMNAT1 FDB muscle. CIII, No evoked action
potential visible in Wld S muscle. CIV, Expected evoked action potentials in an unlesioned fiber.
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(calsyntenin-1) andmicrotubules ( tu-
bulin). There was some heterogeneity,
with Ax-NMNAT1-mCherry fluorescence
occasionally overlappingwithGolgi stain-
ing (-adaptin) in the soma, and more
frequent colocalization with MitoTracker
within axons (Fig. 9J). Time-lapse imaging
in both DRG (Fig. 9K and supplemental
Movie 1, available at www.jneurosci.org as
supplemental material) and hippocampal
neurons (supplementalMovie2, availableat
www.jneurosci.org as supplemental mate-
rial) revealed a number of Ax-NMNAT1-
mCherry particles undergoing bidirectional
axonal transport coordinated with move-
ments of mitochondria. This is important
because it is highly unlikely to reflect coinci-
dental or transient colocalization. Velocity
of mitochondria movement was similar in
transfectedanduntransfectedneuronswith
pauses between continuous transport
(supplemental Movie 2, available at www.
jneurosci.org as supplemental material),
as described previously (Takenaka et al.,
1990; Kang et al., 2008). The colocalization
was evident on both static and moving mi-
tochondria (supplemental Movie 1, avail-
able at www.jneurosci.org as supplemental
material).
Together, these in vivo and in vitro
data indicate that the highly protective
axonally targeted NMNAT1 concen-
trates to the same subcellular structures
where extranuclear WldS is also traf-
ficked. Ax-NMNAT1 transport is regu-
lated and at least partially coordinated
with the axonal movement of mitochon-
dria, pointing to a contribution by mito-
chondria to the delivery of Ax-NMNAT1
and WldS into axons.
Discussion
These data show that local delivery of
NMNAT1 is essential to delay axonal and
synaptic degeneration, and that even amar-
ginal increase in NMNAT activity in axons
is robustly protective. We extend previous
work showing that WldS protects axons
against drugs affecting microtubule stabil-
ity, demonstrating Ax-NMNAT1 protec-
tion also against nocodazole toxicity for
the first time. Ax-NMNAT1 transport to
axons was necessary to prevent degeneration, and its presence
within axons was sufficient to overcome toxicity from high doses
of axonal transport blockers. This indicates an axonalmechanism
of protection, consistent with the presence of WldS in mouse
distal stumps 1 week after lesion (Beirowski et al., 2009).
Our data also show that NMNAT1 can be transformed into a
highly potent neuroprotective molecule by axonal targeting. We
show here that when targeted to axons by a specific targeting
motif NMNAT1 acquires an efficacy greater than WldS. We re-
solve the question of whether 15-fold overexpression of extranu-
clear NMNAT1 is necessary for protection in vivo (Sasaki et al.,
2009b), demonstrating that very low levels preserve axons and
their synaptic endings if NMNAT1 is axonally targeted. Western
blotting with two different primary antibodies, immunohisto-
chemistry and NMNAT enzyme assays unanimously indicated
low to undetectable levels of expression ofAx-NMNAT1 in trans-
genic mice. Because WldS protective efficacy is dose dependent
(Mack et al., 2001), axon protection would not be expected at
such low levels, but low doses of axonally targeted NMNAT1
delay Wallerian degeneration for even 5 weeks. Moreover, nei-
ther a heterozygous dose of WldS protein in young mice nor a
homozygous dose in older mice is sufficient to delay NMJ dener-
Figure 7. Blockage of axonal entry abolishes Ax-NMNAT1 protective capacity. A, Diagram illustrating vincristine and nocoda-
zole application (gray bars) at the indicated times to DRG neurons coexpressing EGFP and Ax-NMNAT1-mCherry. Vincristine was
applied at 0.04M (i and ii), and nocodazole at 5 or 20g/ml (iii and iv), at the time of transfection (ii and iv), or 24 h later at the
time of axotomy (i and iii). B, Representative EGFP epifluorescence images of DRGs expressing Ax-NMNAT1-mCherry, at the time
of axotomy (I ) and 48 h later (II ), treatedwith 0.04M vincristine (i and ii), orwith 20g/ml nocodazole (iii and iv), at the times
indicated inA. Dashed linemarks the cut location. C, Quantification of axonal preservation 48 h after axotomy (imaging II) in DRGs
cultured and treated as explained in A. The diagram shows the percentage of axons (SD) that did not develop swelling or
fragmentation between imaging I and imaging II. D, Diagram illustrating 0.04M vincristine, and 20g/ml nocodazole treat-
ments on DRG explant cultures from wild-type mice and Ax-NMNAT1 homozygotes from line 1. Treatments started 6 d after
plating, 24 h before axotomy. E, Phase-contrast images (0.3mm 0.3mm) of Ax-NMNAT1 orwild-type explants, as indicated, at
the time of cut (I ) and 6 d later (II ), treated with vincristine as illustrated in D. F, Phase-contrast images (0.3 mm 0.3 mm) of
Ax-NMNAT1orwild-type, as indicated, at the timeof cut (I ) and6d later (II ), treatedwithnocodazole as illustrated inD. Scalebars:
B, E, F, 0.1 mm.
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vation (Gillingwater et al., 2002;Wong et al., 2009), whereas these
very low doses of axonally targeted NMNAT1 preserve axoto-
mized NMJs for 6 d and retain this ability even in older mice.
Even thoughAx-NMNAT1 has substantially higher potency than
WldS, important similarities indicate that its mechanism of pro-
tection is the same as the WldS mechanism. Ax-NMNAT1 pro-
tection efficacy was also dose dependent, and axonal atrophy and
fragmentation in Ax-NMNAT1 mice followed a proximo-distal
gradient (Beirowski et al., 2005).
These data strongly suggest that WldS acts locally within ax-
ons. We cannot rule out the possibility that low somatic
NMNAT1 activity increases the expression or transport of an
axonal effector, but this seems unlikely in view of our previous
data demonstrating that a truncated form of WldS, N16 WldS,
is inefficient in protecting axons despite its extranuclear localiza-
tion and enzymatic activity (Conforti et al., 2009).
An axonal role for WldS and Ax-NMNAT1 has several inter-
esting implications for themechanism ofWallerian degeneration
and synapse loss in disease. It has been postulated that depletion
below a critical threshold of transported substances essential
for axonal integrity triggers Wallerian degeneration (Lubin´-
ska, 1977). We recently identified NMNAT2 as a survival fac-
tor in wild-type axons (Gilley and Coleman, 2010). We
proposed that in WldS nerves axonal delivery of this NMNAT1
fusion protein compensates for the postinjury depletion of
NMNAT2. This study now confirms one key prediction of that
proposal: that WldS itself acts in axons.
Additionally as the peculiar degeneration of WldS axons pro-
ceeds proximo-distally independently from the type of injury
(Beirowski et al., 2005), this could reflect a spatial gradient of
WldS loss along the nerve. The weakerWldS protection at NMJs,
compared to the axonal trunk (Gillingwater et al., 2002), could be
explained by the longer distance that WldS needs to travel to
reach the nerve endings and by dilution into the extensive termi-
nal axonal branches. The age dependence of synapse withdrawal
could be due to progressive decrement of axonal transport effi-
ciency correlatingwith aging. At least in some cases, axonal trans-
port decreases along the nerve with a proximo-distal gradient
(Brunetti et al., 1987). Indeed NMNAT could have a local synap-
tic role since the singleDrosophilaNMNAT isoform is also local-
ized at NMJs (Zhai et al., 2006).
The same model could explain why WldS retards anterograde
degenerationmore effectively than retrograde degeneration in some
models of Parkinson’s disease (Cheng and Burke, 2010). Consistent
with this, optimizing the delivery of extranuclear NMNAT1 in this
present report enhances NMJ protection in older mice. This is par-
ticularly important for pathologies in which synapses are affected at
early stages, such as amyotrophic lateral sclerosis (ALS). WldS has
been proven protective for axons in many diseases but was
relatively ineffective in SOD1G93A transgenic mice, the most
widely used model for familial ALS (Coleman, 2005; Fischer et
al., 2005), and failed to reduce symptoms in others (Mi et al.,
2005). Interestingly, although protection depends on trans-
port of NMNAT1 to axons, degeneration caused by axonal trans-
Figure 8. Localization of Ax-NMNAT1 protein in subcellular fractions.A, Brain subcellular fractions fromhemizygous Ax-NMNAT1mice, and variant and nativeWld Smice (blots representative of
3 independent experiments).Membranes fromnegative littermate (WT) andAx-NMNAT1micewere probedwith anti-NMNAT1 antibody 183 (left two panels) andmembrane fromNLSWld S and
Wld Smicewere probedwithWld18 antibody (right two panels). Additional probingwith the organellemarkers validates fraction purity: anti-adaptin for Golgi-enriched fractions, anti-p38 SNPH
for synaptic vesicles-enriched fractions, anti-calnexin for ER-enriched fractions, anti-Sp1 for nuclear-enriched fractions, and anti-prohibitin for mitochondrial-enriched fractions. H, Total homoge-
nate; N, nuclear-enriched fraction; PN, postnuclear fraction; M, mitochondrial-enriched fraction; Vo, V1, V2, vesicle fractions; C, cytosol. Ponceau S indicates the amount of loaded protein. B,
Densitometry of Ax-NMNAT1,NLSWld S, andWld S band intensity in the respective organelle-enriched fractions. Because in each fraction the quantified protein is depleted or concentrated from
the total homogenate, the intensities are expressed as percentage of the band intensity in the respective H fraction. Ax-NMNAT1 and (variant)Wld S protein appear concentrated in vesicle fractions
with intensity correlating with the p38 SNPH intensity, and Ax-NMNAT1 is particularly concentrated also in the mitochondrial fraction.
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port block is delayed if Ax-NMNAT1 has been delivered to axons
before the damage occurred. This could explain the great protec-
tion WldS exerted in the pmn model (Ferri et al., 2003). Thus,
enhanced targeting of WldS or NMNAT1 locally may help pre-
serving synapses and counteract damage caused by axonal trans-
port blockage.
AxonalWldS can be detected in the form of granular staining in
vivo and in multisize particles in vitro. We show that Ax-NMNAT1
andextranuclearWldS shareacommonsubcellular location in small
membranous compartments, in particular subcellular fractions en-
riched inmitochondria, Golgi, and synaptic vesicles. In this context,
we show for the first time coordinated movement of Ax-NMNAT1
with mitochondria in axons, in line with the previously dem-
onstrated association between NLS WldS and mitochondria
(Beirowski et al., 2009).
In view of the employed axonal targeting motif, the mitochon-
drial association seems surprising. The targeting sequence is part of
the C-terminal cytoplasmic domain of APP, which, after cleavage
Figure 9. Localization of Ax-NMNAT1 protein in transfected primary cultures.A, Confocal z-projection of the subcellular distribution of Ax-NMNAT1-mCherry in transfected hippocampal neuron.
B, Single confocal plane of the axonal inset inA. C, Confocal z-projection of Ax-NMNAT1-mCherry andNLSWld S-EGFP cotransfected hippocampal neuron.D, Single confocal plane of the soma and
axon insets in C. E, F, Confocal z-projection of the subcellular distribution of Ax-NMNAT1-mCherry in transfected DRG and its growth cone respectively. G, Single confocal plane of the inset in F;
arrowheads point to Ax-NMNAT1-mCherry puncta at the growth cone. H, I, Single confocal plane of soma and axon, respectively, of an Ax-NMNAT1-mCherry andNLS Wld S-EGFP cotransfected
DRG. In D,H, and I, arrows indicate partial colocalization of Ax-NMNAT1 withNLSWld S. Scale bars: A, C, E, F, 20m; B, D, G–I, 2m. In A–I, blue is DAPI staining, red is Ax-NMNAT1-mCherry
fluorescence, and green isNLS Wld S-EGFP fluorescence. J, Single confocal plane showing colocalization (arrows) of Ax-NMNAT1-mCherry particles and mitochondria (MitoTracker Green) in a
transfected DRG axon. Scale bar, 2 m. K, Time-lapse imaging of the experiment in J, showing coordinated retrograde movement of an Ax-NMNAT1-mCherry particle (arrow, left) with a
mitochondrion (arrow, right). Images were zoomed from supplemental Movie 1 (available at www.jneurosci.org as supplemental material).
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from the full-length APP, is sorted to the axon in carrier vesicles
(Muresan et al., 2009). The NPTY motif contained in the axonal
targeting peptide is involved in the trafficking of synaptic vesicles. In
Drosophila, it mediates axonal accumulation of synaptic markers
upon APP overexpression (Rusu et al., 2007). Although APP inter-
actswith a vast number of proteins, the 15 aa peptideweused is only
likely to interact withMint/X11, via theNPTYdomain (Russo et al.,
1998).Mint/X11 are adaptors containing distinct domains for bind-
ing various proteins, one of which is the synaptic vesicle fusion pro-
tein Munc18-1 (Okamoto and Su¨dhof, 1997). Mint deletion
produces presynaptic functional deficit inKOmice (Hoet al., 2006),
whereas overexpression ameliorates long-term potentiation deficits
in Alzheimer’s disease mouse models (Mitchell et al., 2009).
Ax-NMNAT1 andWldS are abundant in brain subcellular frac-
tions enriched for Golgi apparatus and ER. Perhaps not coinciden-
tally, a strikingly similar distribution has been observed in neurons
transfected with neurexin, another protein interacting with Mint1.
The exit of neurexin from the ER/Golgi and its trafficking to syn-
apses in vesicles depends on its C-terminal sequence, where the do-
main for interaction with Mint1 resides (Fairless et al., 2008).
Althoughadirect interactionbetweenAPPandkinesin is controver-
sial (Kamal et al., 2001; Lazarov et al., 2005), the exit of vesicles
containing APP from the trans-Golgi-network is mediated by
calsyntenin-1 (Ludwig et al., 2009). Calsyntenin-1 is a neuronal
transmembrane protein transported to axons in vesicular carriers in
a kinesin 1-dependent manner (Konecna et al., 2006; Ludwig et al.,
2009). Strikingly, byusing the same subcellular fractionmethod that
we use in the present study, Ludwig et al. (2009) showed that
calsyntenin-1concentrates in the subcellular vesicle fractionsV0and
V1, where we found Ax-NMNAT1 and WldS mostly present. Al-
though we show that Ax-NMNAT1 does not colocalize with
calsyntenin-1, andp38 SNPH,we cannot exclude a possible colocal-
ization with other vesicles of similar size. In fact, Ax-NMNAT1-
mCherry fluorescence was not confined to mitochondria. In this
context, it is interesting to note evidence for physical connection
between ER andmitochondria (de Brito and Scorrano, 2008).
Since the C-terminal fragment of APP is not reported to be tar-
geted tomitochondria (Devi andAnandatheerthavarada, 2010), it is
possible that the strikingmitochondria localizationofAx-NMNAT1
is determinedbyNMNAT1 itself.Whenectopically present in axons
NMNAT1 may dynamically associate with mitochondria. Accord-
ingly, we noticed a progressive increase in number of cytoplasmic
particles ofNLSWldS-EGFPwith time after transfection (data not
shown). Because NLS WldS cytoplasmic puncta colocalize with
mitochondria (Beirowski et al., 2009) their increase in numbermay
underlie a progressive delivery of WldS and NMNAT1 to these or-
ganelles after transfection. A mitochondrial involvement in the
mechanismofWldS andNMNAT1protectionwouldbe in linewith
recent findings showing that mitochondrial NMNAT3 protects in
vivo (Yahata et al., 2009). Further targeting studies may help to re-
solve whether WldS, NMNAT1, and other axon-protective mole-
cules mechanistically act at a specific axonal location and whether
this coincides with mitochondria.
In summary, our data provide the first evidence that NMNAT1
transport to axons and synapses is indispensable for protection. The
unprotective nuclear NMNAT1 protein was transformed into a
strong inhibitor of Wallerian degeneration by specific targeting to
axons. We shed light on possible axonal sites of action facilitating
future analysis of themolecularmechanism. Importantly, this could
be therapeutically exploited, especially in disorders where synapse
loss is a limiting factor, and the localmechanismof protection could
pave the way for direct intervention in the distal stump of a nerve
after injury.
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